AUM BioTech

As a part of our educational series, today we highlight a publication in Science Immunology entitled 'Activation of mTORC1 at late endosomes misdirects T cell fate decision in older individuals', which describes a strategy to enhance T cell immunity. aumbiotech.com/Publications

New peer-reviewed research in Biomarker Research uses self-delivering RNA silencing FANA A*Os, showing lncRNA TEX41 is upregulated in pediatric B-Cells Acute Lymphoblastic Leukemia and the importance of TEX41 as a novel potential biomarker for diagnosis!

Read the article by checking our latest post on aumbiotech.com/Publications

AUM LifeTech, a preclinical stage gene therapy company and our research collaborator, has been selected by the National Institutes of Health (NIH) to participate in 2021 starting June 10. Joining the largest global biotech partnering event, AUM LifeTech will be presenting update on their therapeutic programs in lung cancer, Parkinson’s Disease, and infectious diseases using self-delivering FANA A*O RNA silencing technology 🧬

We hope to see you there!